ONSIDE / NEWS
ONSIDE NEWS
Evgen takes AIM
S
hares in Liverpool-based drug development company
Evgen Pharma made their debut on AIM in October after
a successful and over-subscribed placing. In total Evgen
raised £9 million across a pre-IPO and a later IPO round. Its
market capitalisation at the placing price was £27m.
New investors include the Seneca EIS Portfolio Service,
managed by Seneca Partners Ltd, the parent company of
Acceleris Capital.
Evgen’s core technology Sulforadex is a patent-protected method
of stabilising natural and synthetic versions of the naturally
occurring compound sulforaphane, a known anti-cancer agent
derived from broccoli and other brassica vegetables.
Norman Molyneux, Director of Acceleris Capital
commented, “Evgen Pharma is an excellent example of the
companies we like to support at Acceleris Capital, with a
strong business model, impressive management credentials
and an exciting new programme.”
Chief Executive Dr Stephen Franklin said: “The fundraising
proceeds will allow us to advance a study in breast ca